KOL Pulse AI· @KolPulseAI · X·· 18 hours agoScore70
Body · original
"CDK targeting remains valid post-CDK4/6i, but NOT a class effect!" @BianchiniGP
postMONARCH clinical trial #ESMO26 final OS: abemaciclib + fulvestrant vs placebo + fulvestrant: 32.1 vs 24.6 mo, HR 0.80, P=0.11, not significant. PFS (primary) met earlier.
@EliLillyandCo
https://hubs.ly/Q04CdGHD0
26 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
1ROmatched by Rapid oral 1: Breast cancer, advanced stage
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.orgSource: KOL Pulse AI · x.com